Publications by authors named "Isabelle Dussault"

Claim this Profile
I
Identification of as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer.
Alexander Spira, Ahmad Awada, Nicolas Isambert, David Lorente, Nicolas Penel, Isabelle Dussault

Front Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
James L Gulley, Jeffrey Schlom, Mary Helen Barcellos-Hoff, Xiao-Jing Wang, Joan Seoane, Isabelle Dussault

Mol Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of : an Efficient Inhibitor of the HDM2-p53 Protein-Protein Interaction.
Michael H Reutershan, Michelle R Machacek, Michael D Altman, Stephane Bogen, Mingmei Cai, Isabelle Dussault

J Med Chem· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
Chia-Chi Lin, Toshihiko Doi, Kei Muro, Ming-Mo Hou, Taito Esaki, Isabelle Dussault

Target Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
Benjamin Tan, Adnan Khattak, Enriqueta Felip, Karen Kelly, Patricia Rich, Isabelle Dussault

Target Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Mustafa Khasraw, Michael Weller, David Lorente, Kathryn Kolibaba, Chee Khoon Lee, Isabelle Dussault

Neurooncol Adv· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1.
Yulia Vugmeyster, Justin Wilkins, Andre Koenig, Samer El Bawab, Isabelle Dussault

Clin Pharmacol Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
Luis Paz-Ares, Tae Min Kim, David Vicente, Enriqueta Felip, Dae Ho Lee, Isabelle Dussault

J Thorac Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Yoon-Koo Kang, Yung-Jue Bang, Shunsuke Kondo, Hyun Cheol Chung, Kei Muro, Isabelle Dussault

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
Changhoon Yoo, Do-Youn Oh, Hye Jin Choi, Masatoshi Kudo, Makoto Ueno, Isabelle Dussault

J Immunother Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types.
Justin J Wilkins, Yulia Vugmeyster, Isabelle Dussault, Pascal Girard, Akash Khandelwal

Adv Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma.
Christian Ihling, Bartholomew Naughton, Yue Zhang, P Alexander Rolfe, Eveline Frick-Krieger, Isabelle Dussault

Front Med (Lausanne)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity.
Corina N A M van den Heuvel, Anna C Navis, Tessa de Bitter, Houshang Amiri, Kiek Verrijp, Isabelle Dussault

Mol Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
Amy D Guertin, Jennifer O'Neil, Alexander Stoeck, Joseph A Reddy, Razvan Cristescu, Isabelle Dussault

Mol Cancer Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
Paul E Hughes, Karen Rex, Sean Caenepeel, Yajing Yang, Yihong Zhang, Isabelle Dussault

Mol Cancer Ther· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.
Alessandro A Boezio, Katrina W Copeland, Karen Rex, Brian K Albrecht, David Bauer, Isabelle Dussault

J Med Chem· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to Discovery of Potent and Selective 8-Fluorotriazolopyridine c-Met Inhibitors.
Emily A Peterson, Yohannes Teffera, Brian K Albrecht, David Bauer, Steven F Bellon, Isabelle Dussault

J Med Chem· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.
Emily A Peterson, Yohannes Teffera, Brian K Albrecht, David Bauer, Steven F Bellon, Isabelle Dussault

J Med Chem· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
Christiane M Bode, Alessandro A Boezio, Brian K Albrecht, Steven F Bellon, Loren Berry, Isabelle Dussault

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.
Longbin Liu, Mark H Norman, Matthew Lee, Ning Xi, Aaron Siegmund, Isabelle Dussault

J Med Chem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.
Mark H Norman, Longbin Liu, Matthew Lee, Ning Xi, Ingrid Fellows, Isabelle Dussault

J Med Chem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
Carol Babij, Yihong Zhang, Robert J Kurzeja, Anke Munzli, Amro Shehabeldin, Isabelle Dussault

Cancer Res· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Marc Payton, Tammy L Bush, Grace Chung, Beth Ziegler, Patrick Eden, Isabelle Dussault

Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.
Alessandro A Boezio, Loren Berry, Brian K Albrecht, David Bauer, Steven F Bellon, Isabelle Dussault

Bioorg Med Chem Lett· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.
Isabelle Dussault, Steven F Bellon

Anticancer Agents Med Chem· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis